Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
82.93(c) 83.61(c) 84.18(c) 84.7(c) 87.25 Last
3 940 168 3 053 563 4 253 237 5 950 225 6 667 060 Volume
-1.39% +0.82% +0.68% +0.62% +3.01% Change
More quotes
Financials (USD)
Sales 2019 46 834 M
EBIT 2019 12 446 M
Net income 2019 8 570 M
Debt 2019 15 394 M
Yield 2019 3,45%
Sales 2020 48 546 M
EBIT 2020 13 582 M
Net income 2020 9 446 M
Debt 2020 11 970 M
Yield 2020 3,60%
P/E ratio 2019 21,01
P/E ratio 2020 19,24
EV / Sales2019 4,86x
EV / Sales2020 4,61x
Capitalization 212 B
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (67.2%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Sector
Pharmaceuticals
Calendar
05/23 | 08:00amInvestor Meeting - Day 2
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
01:24pNOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $425,..
DJ
12:44pNOVARTIS : AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs f..
GL
12:44pNOVARTIS : AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs f..
AQ
12:32pNOVARTIS : AveXis receives FDA approval for Zolgensma®, the first and only gene ..
GL
10:20aSosei Heptares Notes That a Valid Marketing Authorization Application For QVM..
AQ
03:22aVECTURA : Awarded $2.5 Million from Novartis After Drug Makes Regulatory Progres..
DJ
05/23NOVARTIS : CEO says data quality, lagging innovation crimp China M&A
RE
05/23NOVARTIS : CEO says data quality, lagging innovation crimp China M&A
RE
05/23NOVARTIS : CEO sees chance to accelerate profit margin target
RE
05/23NOVARTIS : highlights company transformation, catalyst-rich pipeline, and strong..
GL
More news
Analyst Recommendations on NOVARTIS
More recommendations
Stock Trading Strategies
NOVARTIS - 2018
Technically solid
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
05/23GLAXOSMITHKLINE : GSK brings back bonuses for some sales reps
RE
05/23GLAXOSMITHKLINE : GSK's shingles vaccine approved for use in China in adults age..
RE
05/23GLAXOSMITHKLINE : GSK to change incentives for sales representatives
RE
05/23BAYER : Donates Hemophilia Treatments in New Partnership
DJ
05/23DAIICHI SANKYO : looking to sell OTC drug unit for about $900 million - Nikkei B..
RE
More sector news : Pharmaceuticals - NEC
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 89,6 $
Spread / Average Target 6,2%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS14.01%212 054
JOHNSON & JOHNSON7.52%371 150
PFIZER-3.80%233 072
ROCHE HOLDING LTD.10.72%230 177
MERCK AND COMPANY6.03%208 598
ABBVIE-11.98%119 967